The concern of generic competition has repeatedly loomed around copyright’s iconic drug, Sildenafil, raising questions about the future of similar medicinal stakes. While early times saw substantial returns, the patent expiration has created the door for discounted copies, potentially reducing revenue and creating a genuine hazard for shareholder